Canada’s Drug Agency | Drugs, Health Technologies and Systems.
Canada’s Drug Agency | Drugs, Health Technologies and Systems.

nivolumab ipilimumab

Details

Files
Generic Name:
nivolumab ipilimumab
Project Status:
Complete
Therapeutic Area:
Melanoma
Manufacturer:
N/A
Call for patient/clinician input open:
Brand Name:
N/A
Project Line:
Reimbursement Review
Project Number:
PX0371-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
N/A
Submission Type:
Non-sponsored Submission
Fee Schedule:
Pending
Indications:
​Indicated in neoadjuvant setting for resectable stage III melanoma.
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Key Milestones2
Submission received04-Jul-24
Review initiated05-Jul-24
Expert committee meeting (initial)21-Nov-24
Draft recommendation posted for stakeholder feedback12-Dec-24
End of feedback period03-Jan-25
Final recommendation posted-
CADTH review report(s) posted29-Jan-25

Files

Responses to the Questions From the Drug Programs View PDF
Clinical and Pharmacoeconomic Combined Report View PDF
Combined Report Supplemental Materials View PDF
Patient, Clinician and Industry Input View PDF
Last Updated : January 29, 2025